Search research articles
Contact Us
Filters
Showing results (81-90 of 181) with videos related to
Page
of 19
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
September 21, 2017
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia
Rita Assi, Hagop Kantarjian, Nicholas J Short, et al.
Cancer
|
January 19, 2012
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system
Wei-Gang Tong, Alfonso Quintás-Cardama, Tapan Kadia, et al.
Cancer
|
December 12, 2003
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data
Hagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Cancer
|
June 5, 2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside
Guillermo Garcia-Manero, Moshe Talpaz, Francis J Giles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 22, 2004
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls
Hagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Blood
|
January 13, 2006
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
Stefan Faderl, Srdan Verstovsek, Jorge Cortes, et al.
British Journal of Haematology
|
February 6, 2016
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes
Preetesh Jain, Hagop Kantarjian, Koji Sasaki, et al.
Cancer
|
October 23, 2025
A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens
Hagop M Kantarjian, Gautam Borthakur, Naval Daver, et al.
Cancer
|
February 13, 2026
Clinical, genetic, and familial features of POT1 tumor predisposition syndrome
Courtney D DiNardo, Jennifer Croden, Hiam M Abdel-Salam, et al.
Blood
|
February 1, 2003
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
Jorge E Cortes, Moshe Talpaz, Francis Giles, et al.
Page
of 19
Search research articles
Search
Showing results (81-90 of 181) with videos related to
Sort By:
Page
of 19
Clinical Lymphoma, Myeloma & Leukemia
|
September 21, 2017
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia
Rita Assi, Hagop Kantarjian, Nicholas J Short, et al.
Cancer
|
January 19, 2012
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system
Wei-Gang Tong, Alfonso Quintás-Cardama, Tapan Kadia, et al.
Cancer
|
December 12, 2003
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data
Hagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Cancer
|
June 5, 2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside
Guillermo Garcia-Manero, Moshe Talpaz, Francis J Giles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 22, 2004
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls
Hagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Blood
|
January 13, 2006
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
Stefan Faderl, Srdan Verstovsek, Jorge Cortes, et al.
British Journal of Haematology
|
February 6, 2016
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes
Preetesh Jain, Hagop Kantarjian, Koji Sasaki, et al.
Cancer
|
October 23, 2025
A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens
Hagop M Kantarjian, Gautam Borthakur, Naval Daver, et al.
Cancer
|
February 13, 2026
Clinical, genetic, and familial features of POT1 tumor predisposition syndrome
Courtney D DiNardo, Jennifer Croden, Hiam M Abdel-Salam, et al.
Blood
|
February 1, 2003
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
Jorge E Cortes, Moshe Talpaz, Francis Giles, et al.
Page
of 19